Nanobiotix Balance Sheet Health
Financial Health criteria checks 1/6
Nanobiotix has a total shareholder equity of €-21.8M and total debt of €44.5M, which brings its debt-to-equity ratio to -204.3%. Its total assets and total liabilities are €86.7M and €108.5M respectively.
Key information
-204.3%
Debt to equity ratio
€44.48m
Debt
| Interest coverage ratio | n/a |
| Cash | €66.34m |
| Equity | -€21.78m |
| Total liabilities | €108.46m |
| Total assets | €86.68m |
Recent financial health updates
No updates
Recent updates
Nanobiotix enters final agreement to restructure existing loan with EU's investment bank
Oct 18Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M
Sep 28Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank
Sep 12French biotech Nanobiotix rebounds to post best ever 47% intraday gain
Aug 01Nanobiotix names Bart Van Rhijn as chief financial officer
Jun 01Nanobiotix Will Disrupt Oncological Radiotherapy
Jan 29Financial Position Analysis
Short Term Liabilities: NBTX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NBTX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NBTX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NBTX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NBTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NBTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 02:35 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanobiotix S.A. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mickael Chane-Du | Bryan Garnier & Co |
| Philippa Gardner | Edison Investment Research |
| Jonathan Miller | Evercore ISI |